Charles River Laboratories to acquire MPI Research for $800m

pallavi123- February 14, 2018 0

In a strategic move to bolster its position in the pharmaceutical research sector, Charles River Laboratories International, Inc. has agreed to acquire Michigan-based non-clinical contract ... Read More

Cyclacel Pharmaceuticals’ sapacitabine fails to meet primary endpoint in Phase 3 blood cancer trial

pharmanewsdaily- February 26, 2017 0

Cyclacel Pharmaceuticals, a New Jersey-based biopharmaceutical company, announced that its experimental blood cancer drug, sapacitabine (CYC682), did not meet the primary endpoint in the pivotal ... Read More

1212 / 12 Posts